京都大学 · 医学
Matsuo教授の研究室は、神経内分泌系のホルモン構造と機能の解明を柱としており、特にLH・FSH放出ホルモンのアミノ酸配列解明をはじめとするペプチドホルモンの分子生物学的研究を推進しています。また、造血幹細胞の自己複製制御に関与するEVI1遺伝子やAMLにおける遺伝子異常(CEBPA、MLL)の臨床的意義についても、がん・血液疾患の分子メカニズム解明を目的として研究を展開しています。近年では、画像・血液検査データを活用した機械学習による自己免疫疾患の予後予測にも応用的アプローチをとっています。
Figures are computed from collected data and may differ slightly.
No AccessJournal of Urology1 Feb 2002Structure of the porcine LH-and FSH-releasing Hormone.I. The proposed amino acid sequence0110 0 H. Matsuo, Y. Baba, R.M.G. Nair, A. Arimura, and A.V. Schally H. MatsuoH. Matsuo V.A. Hospital, New Orleans, LA, USA Tulane University School of Medicine, New Orleans, LA, USA More articles by this author , Y. BabaY. Baba V.A. Hospital, New Orleans, LA, USA Tulane University School of Medicine, New Orleans, LA, USA More articles by this author , R.M.G. NairR.M.G. N
The ecotropic viral integration site-1 gene (EVI1) encodes a zinc finger protein that functions as a transcriptional regulator of hematopoietic stem cell self-renewal and long-term multilineage repopulating activity. The mixed lineage leukemia gene (MLL) rearrangements [i.e. t(11q23)] occur at high frequency in pediatric acute myeloid leukemia (AML) patients with EVI1 overexpression, 3 and EVI1 is a transcriptional target of MLL oncoproteins. 4 EVI1 overexpression has been reported in up to 10%
Recent effective therapies enable most rheumatoid arthritis (RA) patients to achieve remission; however, some patients experience relapse. We aimed to predict relapse in RA patients through machine learning (ML) using data on ultrasound (US) examination and blood test. Overall, 210 patients with RA in remission at baseline were dichotomized into remission (n = 150) and relapse (n = 60) based on the disease activity at 2-year follow-up. Three ML classifiers [Logistic Regression, Random Forest, an
CCAAT/enhancer-binding protein alpha (CEBPA) mutations are a favorable prognostic factor in adult acute myeloid leukemia (AML) patients; however, few studies have examined their significance in pediatric AML patients. Here we examined the CEBPA mutation status and clinical outcomes of pediatric AML patients treated in the AML-05 study. We found that 47 (14.9%) of the 315 evaluable patients harbored mutations in CEBPA; 26 cases (8.3%) harbored a single mutation (CEBPA-single) and 21 (6.7%) harbor
Open papers in the app to read, cite, and organize with AI.